Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). This product is a bioequivalent and therapeutically equivalent version of the reference drug Travatan Z® Ophthalmic Solution USP, 0.004% by Sandoz, Inc.
According to IQVIA™ sales data, the Travatan Z® market recorded annual sales of approximately $66.2 million for the 12-month period ending September 2024, highlighting the significant market opportunity for Glenmark’s new product.
Commitment to Ophthalmic Care
Jim Brown, Senior Vice President of Sales & Marketing at Glenmark, expressed the company’s enthusiasm about the launch:
“We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers.”
Expanding U.S. Portfolio
Glenmark’s U.S. portfolio currently includes 200 products authorized for distribution and 51 ANDAs pending FDA approval. The company continues to enhance its pipeline by pursuing external development partnerships, reinforcing its position as a key player in the U.S. pharmaceutical market.
This launch marks another step forward in Glenmark’s strategy to offer high-quality, cost-effective solutions to patients and healthcare providers across the U.S.
